Celldex Therapeutics (CLDX) 10-K2005 FY Annual report

Filed: 16 Mar 06, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: affiliate, Agriculture, alleged, alleging, ArgusTM, attestation, Australia, billable, Biostability, book, Cambridge, CCH, Circulation, clear, correction, Crucell, deplete, distinction, entirety, error, EU, exact, fringe, Glaser, incremental, index, Innovata, installation, interaction, Intercell, internationally, Lancet, light, listed, monetization, mutated, opt, pathway, Paul, payer, penetration, point, PRF, remitted, renovation, rentable, requisite, retirement, retrospective, retrospectively, Roche, Ronald, SBL, Science, scrutiny, STOCKHOLDER, stream, unamortized, unconditional, Union, unpredictable, unrecognized, unused

Removed: academia, accelerated, accumulation, Adjumer, adjuvant, AG, againstCampylobacter, againstSalmonella, allotransplantation, atherosclerotic, attractive, bacteriumVibrio, bad, Basel, Berna, Bio, Biomedical, booster, check, collaborating, commencing, compute, construed, delinquent, discovered, economically, Employer, enterotoxigenice, enterprise, Exclusion, executed, existingShigella, fatty, filer, formed, geographically, headquartered, ID, identification, inin, inLancet, Japan, knowledge, likelihood, managed, mark, Micromer, microscience, mutatedVibrio, ofB, ofSalmonella, ofScience, ourCholera, parallel, PCPP, polymer, polyphosphazene, PPD, preceding, preventing, respiratory, returned, RSV, standard, suggesting, Switzerland, syncytial, telephone, Tobacco, vectored, Washington, withShigella, xenotransplantation, young

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CLDX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Forms S-8, (File Nos. 333-52796, 333-34780, 33-80036, 33-80050, 333-62017, 333-117601 and 333-117602) and the Registration Statements on Forms S-3 (File Nos. 333-64704, 333-43204, 333-52736, 33-64021, 333-08607, 333-56755, 333-64761, 333-89341, 333-109583 and 333-106918) of AVANT Immunotherapeutics, Inc. of our report dated March 16, 2006 relating to the financial statements, management’s assessment of the effectiveness of internal control over financial reporting, and the effectiveness of internal control over financial reporting which appears in this Form 10-K.

/s/ PricewaterhouseCoopers
Boston, Massachusetts
March 16, 2006